Hints and tips:
...Novo Nordisk and Eli Lilly have struggled to keep up with soaring demand for obesity treatments....
...The same dog-avoidance benefit probably contributed to actives beating passives last year in Denmark, where selling Ørsted and Genmab on the first sniff of trouble while holding on to Novo Nordisk would...
...Trading at around 9 times forward earnings, a fraction of peers Eli Lilly and Novo Nordisk....
...Novo Nordisk, Eli Lilly’s Danish rival, has also soared. But investors who were hoping for a more general broadening of market gains have so far been disappointed....
...Need to know: business Novo Nordisk announced a €1bn deal for a German biotech developing therapies to treat heart disease, as the Danish group seeks to branch out from its blockbuster diabetes and weight...
...The top five contributors to the fund’s performance last year were Meta Platforms, Microsoft, Novo Nordisk, L’Oréal and IDEXX Laboratories....
...Baras said the GLP-1 drugs from Novo Nordisk and Eli Lilly had been a “fantastic development for the field”....
...Like a similar drug from Novo Nordisk, it targets a brain area that regulates appetite....
...“That [manufacturing] expertise will be important, especially with diabetes, which is more of a primary care market,” said Chen, adding that rivals Lilly and Novo Nordisk have experienced supply issues because...
...Novo Nordisk, which has a reasonably active non-kroner quote, outperforms. Pandora, which doesn’t, doesn’t....
...But of course, we don’t expect Novo Nordisk to solve all the problems related to the way food is treated in our culture....
...Novo Nordisk’s Saxenda seemed a winner: sales last year surged 47 per cent to DKr5.68bn ($898m)....
...A company that exemplifies the benefits of long-term controlling stewards is Novo Nordisk, the Danish drug company....
...Novo Holdings manages the $60bn portfolio of the Novo Nordisk Foundation, a Danish medical and research charity....
...They include a mix of healthcare, consumer staples and tech: GlaxoSmithKline, Roche, ASML, Nestlé, Novartis, Novo Nordisk, L’Oréal, LVMH, AstraZeneca, SAP and Sanofi....
...As diabetic patients have shared horror stories about not being able to afford insulin, Sanofi and rivals Eli Lilly and Novo Nordisk have come under fire for price increases on the essential medicine....
...Celgene, the biotech group, and Novo Nordisk, the diabetes drugmaker, have also increased their prices more than once in 2018, as have a series of lesser-known companies....
...(FT) News round-up Sanofi beats Novo Nordisk with €3.9bn Ablynx deal (FT) Sanofi/Novo Nordisk: blood money (FT Lex) Dell is considering a sale to VMware in what may be tech’s biggest deal ever (CNBC)...
...Mr Schultz, who formerly also worked as chief operating officer at Novo Nordisk, succeeds Yitzhak Peterburg....
...Nordisk to “buy” — Ingenico cut to “neutral” at Citi — Société Générale upgrades Eon to “buy”....
...However, the two investments being announced today, on top of moves by AstraZeneca to make its headquarters in Cambridge and Novo Nordisk to fund a diabetes research centre in Oxford suggested “we are seeing...
...Several other well-known pharmaceutical groups, including Novo Nordisk and Shire are working on Nash drugs at an earlier stage of development....
...Smart reads David v Goliath Large consumer goods companies are starting to feel the impact of their smaller, more innovative rivals....
...Also on board were the US heads of the European groups BASF, Novo Nordisk, Shell, Solvay Chemicals and Zurich Insurance, as well as leaders from Mahindra of India, Samsung of South Korea, Japan’s Panasonic...
...Pfizer increased its prices even after many rivals, including AbbVie, Allergan, Sanofi and Novo Nordisk, pledged to limit increases amid popular anger and a pledge from Mr Trump to stop the industry “getting...
International Edition